Specialty Pharmaceutical Revenue Growth Driven by Niche Demand

by Andrew Berens, MD, Senior Healthcare Analyst, Bloomberg Industries


Increasing demand in niche therapeutic areas has driven 11 percent revenue growth among specialty pharmaceutical companies during the last five years. The sector has benefited from new product launches, fresh income streams from label expansions and entry into diversified geographical markets. Mergers and acquisitions has also bolstered pipelines and continued sales growth.


Read More >>>>>

Bloomberg BRIEF Newsletters